Literature DB >> 21075869

Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction.

Dirk Westermann1, Diana Lindner, Mario Kasner, Christine Zietsch, K Savvatis, F Escher, J von Schlippenbach, C Skurk, Paul Steendijk, Alexander Riad, Wolfgang Poller, Heinz-Peter Schultheiss, Carsten Tschöpe.   

Abstract

BACKGROUND: The pathophysiology of heart failure with normal ejection fraction (HFNEF) is still under discussion. Here we report the influence of cardiac inflammation on extracellular matrix (ECM) remodeling in patients with HFNEF. METHODS AND
RESULTS: We investigated left ventricular systolic and diastolic function in 20 patients with HFNEF and 8 control patients by conductance catheter methods and echocardiography. Endomyocardial biopsy samples were also obtained, and ECM proteins as well as cardiac inflammatory cells were investigated. Primary human cardiac fibroblasts were outgrown from the endomyocardial biopsy samples to investigate the gene expression of ECM proteins after stimulation with transforming growth factor-β. Diastolic dysfunction was present in the HFNEF patients compared with the control patients. In endomyocardial biopsy samples from HFNEF patients, we found an accumulation of cardiac collagen, which was accompanied by a decrease in the major collagenase system (matrix metalloproteinase-1) in the heart. Moreover, a subset of inflammatory cells, which expressed the profibrotic growth factor transforming growth factor-β, could be documented in the HFNEF patients. Stimulation of primary human cardiac fibroblasts from HFNEF patients with transforming growth factor-β resulted in transdifferentiation of fibroblasts to myofibroblasts, which produced more collagen and decreased the amount of matrix metalloproteinase-1, the major collagenase in the human heart. A positive correlation between cardiac collagen, as well as the amount of inflammatory cells, and diastolic dysfunction was evident and suggests a direct influence of inflammation on fibrosis triggering diastolic dysfunction.
CONCLUSIONS: Cardiac inflammation contributes to diastolic dysfunction in HFNEF by triggering the accumulation of ECM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21075869     DOI: 10.1161/CIRCHEARTFAILURE.109.931451

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  200 in total

Review 1.  Where Does Inflammation Fit?

Authors:  Luigi M Biasucci; Giulio La Rosa; Daniela Pedicino; Alessia D'Aiello; Mattia Galli; Giovanna Liuzzo
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

Review 2.  Extracellular Matrix and Regenerative Therapies from the Cardiac Perspective.

Authors:  Arin Dogan; Mahmut Parmaksız; A Eser Elçin; Y Murat Elçin
Journal:  Stem Cell Rev Rep       Date:  2016-04       Impact factor: 5.739

Review 3.  Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.

Authors:  Fayez El Shear
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

4.  Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization.

Authors:  Hiroe Toba; Lisandra E de Castro Brás; Catalin F Baicu; Michael R Zile; Merry L Lindsey; Amy D Bradshaw
Journal:  Am J Physiol Cell Physiol       Date:  2015-04-15       Impact factor: 4.249

5.  The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells.

Authors:  Zuyue Sun; Jill Schriewer; Mingxin Tang; Jerry Marlin; Frederick Taylor; Ralph V Shohet; Eugene A Konorev
Journal:  J Mol Cell Cardiol       Date:  2015-12-11       Impact factor: 5.000

6.  Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction.

Authors:  Scott L Hummel; E Mitchell Seymour; Robert D Brook; Theodore J Kolias; Samar S Sheth; Hannah R Rosenblum; Joanna M Wells; Alan B Weder
Journal:  Hypertension       Date:  2012-10-01       Impact factor: 10.190

7.  Mechanisms of atrial fibrillation in aged rats with heart failure with preserved ejection fraction.

Authors:  Thassio Ricardo Ribeiro Mesquita; Rui Zhang; Geoffrey de Couto; Jackelyn Valle; Lizbeth Sanchez; Russell G Rogers; Kevin Holm; Weixin Liu; Eduardo Marbán; Eugenio Cingolani
Journal:  Heart Rhythm       Date:  2020-02-15       Impact factor: 6.343

Review 8.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

Review 9.  Obstructive Sleep Apnea in Heart Failure: Review of Prevalence, Treatment with Continuous Positive Airway Pressure, and Prognosis.

Authors:  Himad K Khattak; Faisal Hayat; Salpy V Pamboukian; Harvey S Hahn; Brian P Schwartz; Phyllis K Stein
Journal:  Tex Heart Inst J       Date:  2018-06-01

Review 10.  Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.

Authors:  Erik H Howell; Scott J Cameron
Journal:  Cardiol J       Date:  2016-09-26       Impact factor: 2.737

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.